Novel Combinations of Radiation and Immunotherapy

作为一名拥有癌症生物学和普通免疫学研究生和博士后培训的放射肿瘤学家，我研究的最终目标是发现将免疫治疗（IT）与放射治疗（RT）相结合的有效方法，以促进肿瘤的全身控制，同时实现肿瘤的局部控制。为了实现这一目标，在加入NCI之前，我和斯坦福大学的苏珊·诺克斯（Susan Knox）一起开展了一项临床试验，编号NCT01449279。为了支持NCI的RT + IT试验的发展，并建立在NCI内部项目的现有项目优势上，我正在与George Pavlakis (NCI/VB)， Thomas Waldmann和Kevin Conlon （NCI/LMB）合作，在临床前模型中测试il -15 + RT和hetIL-15 + RT，我是ROB的主要副研究员，与Tim Greten和Austin Duffy （NCI/TGIB）一起研究NCI的结肠直肠肝脏转移（15-C-0021）和胰腺（15-C-0027） RT + IT研究。最终，我们计划研究免疫治疗试验（如RT + IT试验、NCI VB疫苗试验和NCI的其他肿瘤免疫治疗试验）中应答者和无应答者的EV亚群，将EV亚群特征转化为可用于患者个性化和适应性治疗的生物信息。

As a radiation oncologist with graduate and postdoctoral training in both cancer biology and general immunology, the ultimate goal of my research is to discover effective ways to combine immunotherapies (IT) with radiation therapy (RT) to promote systemic tumor control while achieving local tumor control. Toward this goal, I opened a clinical trial, NCT01449279, with Susan Knox at Stanford, prior to joining NCI. To support the development of RT + IT trials at NCI, and to build upon existing programmatic strengths of the NCI intramural program, I am collaborating with George Pavlakis (NCI/VB), Thomas Waldmann and Kevin Conlon (NCI/LMB) to test rIL-15 + RT and hetIL-15 + RT in preclinical models, and I am the primary ROB Associate Investigator working with Tim Greten and Austin Duffy (NCI/TGIB) on NCI's colorectal liver metastases (15-C-0021), and pancreas (15-C-0027) RT + IT studies. Ultimately, we plan to study EV subsets in responders and non-responders from immunotherapy trials (such as these RT + IT trials, NCI VB vaccine trials, and other tumor immunotherapy trials at NCI), to translate the EV subset signatures into biological information that could be used for personalized and adaptive treatments for our patients.